Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice

被引:6
作者
Sarin, PS
Talmadge, JE
Heseltine, P
Murcar, N
Gendelman, HE
Coleman, R
Kelsey, L
Beckner, S
Winship, D
Kahn, J
机构
[1] CEL SCI Corp, Vienna, VA 22182 USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
[3] Univ So Calif, Dept Med, Los Angeles, CA USA
[4] San Francisco Gen Hosp, San Francisco, CA 94110 USA
[5] Dept Med, San Francisco, CA USA
关键词
HGP-30; HIV-1; vaccine; SCID mice;
D O I
10.1016/S0264-410X(98)00119-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Eleven HIV-1 seronegative subjects previously injected with an HIV-1 p17 synthetic peptide vaccine (HGP-30) were given two booster immunizations to evaluate memory cell responses and the ability to boost cellular and humoral immune responses. Five of 11 subjects showed a significant increase in their antibody titres to HGP-30 or p17 and 6/11 had T-cell proliferation responses to either HGP-30 or p17. HIV-1 virus challenge studies in SCID mice demonstrated that 39 of 50 mice (78%) receiving PBMC from 5 of the HGP-30 immunized subjects were protected from infection with a different strain of HIV-1 compared to 4 of 30 mice (13%) that received PBMC from 3 non-immunized subjects (p < 0.001). These studies show that booster immunizations with HGP-30 vaccine are safe and non-toxic and induce protective cell mediated immune responses. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:64 / 71
页数:8
相关论文
共 40 条
  • [1] HGP-30, A SYNTHETIC ANALOG OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) P17, IS A TARGET FOR CYTOTOXIC LYMPHOCYTES IN HIV-INFECTED INDIVIDUALS
    ACHOUR, A
    PICARD, O
    ZAGURY, D
    SARIN, PS
    GALLO, RC
    NAYLOR, PH
    GOLDSTEIN, AL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (18) : 7045 - 7049
  • [2] BANDER C, 1996, HIV MOL IMMUNOLOGY D, V4, P50
  • [3] VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    BORROW, P
    LEWICKI, H
    HAHN, BH
    SHAW, GM
    OLDSTONE, MBA
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (09) : 6103 - 6110
  • [4] NEUTRALIZATION OF HIV-1 BY SECRETORY IGA INDUCED BY ORAL IMMUNIZATION WITH A NEW MACROMOLECULAR MULTICOMPONENT PEPTIDE VACCINE CANDIDATE
    BUKAWA, H
    SEKIGAWA, KI
    HAMAJIMA, K
    FUKUSHIMA, J
    YAMADA, Y
    KIYONO, H
    OKUDA, K
    [J]. NATURE MEDICINE, 1995, 1 (07) : 681 - 685
  • [5] CELL-MEDIATED-IMMUNITY IN HIV-INFECTION
    CLERICI, M
    [J]. AIDS, 1993, 7 : S135 - S140
  • [6] A T(H)1-]T(H)2 SWITCH IS A CRITICAL STEP IN THE ETIOLOGY OF HIV-INFECTION
    CLERICI, M
    SHEARER, GM
    [J]. IMMUNOLOGY TODAY, 1993, 14 (03): : 107 - 110
  • [7] HIV-Specific cellular and humoral immune responses in primary HIV infection
    Connick, E
    Marr, DG
    Zhang, XQ
    Clark, SJ
    Saag, MS
    Schooley, RT
    Curiel, TJ
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (12) : 1129 - 1140
  • [8] Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
    Connor, RI
    Korber, BTM
    Graham, BS
    Hahn, BH
    Ho, DD
    Walker, BD
    Neumann, AU
    Vermund, SH
    Mestecky, J
    Jackson, S
    Fenamore, E
    Cao, Y
    Gao, F
    Kalams, S
    Kunstman, KJ
    McDonald, D
    McWilliams, N
    Trkola, A
    Moore, JP
    Wolinsky, SM
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (02) : 1552 - 1576
  • [9] HUMAN STUDIES IN THE DEVELOPMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS VACCINES
    DOLIN, R
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (05) : 1175 - 1183
  • [10] HIV PREVENTIVE VACCINES - PROGRESS TO DATE
    ESPARZA, J
    OSMANOV, S
    HEYWARD, WL
    [J]. DRUGS, 1995, 50 (05) : 792 - 804